Objective: Since the advent of induced pluripotent stem cell (iPSC) technology a decade ago, enormous progress has been made in stem cell biology and regenerative medicine. Human iPSCs have been widely used for disease modeling, drug discovery, and cell therapy development. In this review, we discuss the progress in applications of iPSC technology that are particularly relevant to drug discovery and regenerative medicine, and consider the remaining challenges and the emerging opportunities in the field.
Data sources: Articles in this review were searched from PubMed database from January 2014 to December 2017.
Study selection: Original articles about iPSCs and cardiovascular diseases were included and analyzed.
Results: iPSC holds great promises for human disease modeling, drug discovery, and stem cell-based therapy, and this potential is only beginning to be realized. However, several important issues remain to be addressed.
Conclusions: The recent availability of human cardiomyocytes derived from iPSCs opens new opportunities to build in vitro models of cardiac disease, screening for new drugs and patient-specific cardiac therapy.
人诱导多能干细胞是否是最优的选择摘要目的：自十多年前诱导性多能干细胞（iPSC）技术问世以来，干细胞生物学和再生医学取得了巨大的进展。人类iPSC已广泛用于疾病建模，药物发现和细胞治疗。在这篇综述中，我们将讨论与药物发现和再生医学相关的iPSC技术应用的进展，并考虑在该领域中面临的挑战和新兴的机会。 数据来源：本评价文章均从2014年1月至2017年12月从PubMed数据库中搜索。 研究选择：包括并分析关于iPSC和心血管疾病的原始文章。 结果：iPSC对人类疾病模型，药物发现和基于干细胞的治疗抱有很好的前景，这种潜力才刚刚开始实现。但是，有几个重要问题仍有待解决。 结论：最近获得来自iPSC的人心肌细胞为开发心脏疾病的体外模型，筛选新药物和患者特异性心脏治疗开辟了新的机会。.
Keywords: Cardiovascular Diseases; Embryonic Stem Cells; Induced Pluripotent Stem Cells.